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Retinoids in nephrology: Promises and pitfalls.
Background. Retinoids, a family of vitamin A metabolites or
analogs, play an important role in regulating cell proliferation,
differentiation, and apoptosis.
Methods. The biological importance of retinoids in the kidney
and the potential of retinoids in the treatment of renal diseases
are reviewed.
Results. Vitamin A deficiency and mutations of retinoid nu-
clear receptors cause abnormalities in fetal kidneys, which might
predispose to adult diseases such as hypertension. Further,
the therapeutic value of retinoids in animal models of kid-
ney diseases, such as lupus nephritis, puromycin aminonucleo-
side nephrosis, anti-glomerular basement membrane nephritis,
mesangioproliferative nephritis, and acute renal allograft re-
jection has been unveiled recently. Retinoids target mesangial
cells, podocytes, tubular epithelial cells, interstitial fibroblasts, as
well as lymphocytes and macrophages. The anti-inflammation,
anti-coagulation effects, and the proliferation- and immunity-
modulating actions of retinoids, have been widely appreciated.
Our recent in vitro data revealed a direct antifibrotic effect and
a cytoprotective effect of retinoids in various renal cell types.
In animal studies, the adverse effects of retinoids are gener-
ally minimal; however, the clinical use of retinoids in other dis-
eases points to some major side effects. In addition, in vitro,
retinoids can induce lipid accumulation in smooth muscle cells
and macrophages and increase expression of some proinflam-
matory molecules, indicating that their clinical toxicity profile
in the setting of renal diseases needs to be better understood.
Conclusion. Retinoids not only are important in renal devel-
opment, but also show promise as a new generation of renal
medication and deserve to be tested in clinical trials to clarify
their full potential.
Identification of new therapeutic agents has always
been an important challenge for nephrologists. Recently,
retinoids, a family of vitamin A metabolites or analogs,
have been shown to have excellent preventive and thera-
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peutic effects in various experimental kidney diseases, as
shown in Table 1 [1–18]. To date, three groups of retinoids
have been isolated or synthesized (Table 2) [1–4, 6, 12,
13, 19, 20]. The first group are natural provitamin A, vi-
tamin A, and other retinoic acid (RA) precursors, which
cannot bind retinoid nuclear receptors, but are charac-
terized by their potential to be converted into RAs; the
second group includes the natural RAs, including all-
trans-RA (tRA) and 13-cis-RA (13cRA), which bind and
activate RA receptors (RARs), and 9-cis-RA (9cRA),
which binds and activates both RARs and retinoid X re-
ceptors (RXRs). The third group is composed of synthetic
retinoids, which bind one or more RAR or/and RXR iso-
types and exert agonistic or antagonistic actions. Some
of the third group activate neither RARs nor RXRs,
but have selective anti-activator protein-1 (anti-AP-1)
activity [2].
Although vitamin A does not bind any of the nu-
clear receptors, the majority of its functions are retinoid
nuclear receptor–dependent; therefore, conversion of
vitamin A into RAs that can bind retinoid nuclear re-
ceptors is largely a process of vitamin A activation [21]
(Fig. 1). The activation of vitamin A occurs via two oxida-
tion steps. It is first converted to retinaldehyde, and then
to tRA. Conversion from vitamin A to retinaldehyde is a
reversible process that is catalyzed by alcohol dehydroge-
nases (ADHs) and short-chain dehydrogenases. The irre-
versible conversion of retinaldehyde to RA is catalyzed
by retinaldehyde dehydrogenases (RALDHs), which are
the key enzymes of RA synthesis [21]. It is known that
tRA is the major biologically active retinoid in both
embryonic and adult tissues and that, catalyzed by iso-
merases, tRA, 13cRA, and 9cRA can be interconverted
[22]. The metabolism of RAs is catalyzed by a group of cy-
tochrome P450 (Cyp) enzymes. For example, metabolism
of tRA is mainly mediated by Cyp26, which converts tRA
to 4-hydroxy-RA and 4-oxo-RA [22]. Although there is
compelling evidence to show that 4-hydroxy-RA and 4-
oxo-RA are not involved in physiologic retinoid signal-
ing during mouse development [23], at pharmacologic
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Table 1. Effects of retinoids on animal models of renal disease
Response
Model to RAs References
Acute Thy1.1 nephritis + [1, 2]
Chronic Thy1.1 nephritis + [3, 4]
Puromycin aminonucleoside nephrosis + [5, 6]
Lupus nephritis + [7]
Acute kidney allograft rejection + [8]
Aging related nephropathy + [9, 10]
Unilateral ureteral obstruction + [11]
Pyelonephritis + [12, 13]
Anti-GBM nephritis (chronic phase) + [14]
Anti-GBM nephritis (acute phase) ± [15]
Radiation nephritis − [16–18]
Note: +, renal damage reduced; ±, proteinuria unchanged; −, renal damage
enhanced.
concentrations they can activate nuclear receptors and
induce cell differentiation [22]. Therefore, the pharmaco-
logic importance of RA metabolites needs to be further
defined.
RETINOIDS: MECHANISMS OF ACTION
RAR-, RXR-, and RA response element
(RARE)-mediated gene regulation
Biologically active retinoids are characterized by their
capacity to bind and activate retinoid nuclear recep-
tors, including RARs and/or RXRs. These receptors are
ligand-regulated transcription factors with essential roles
in embryonic development and adult physiology, and
each has three isotypes (a, b , and c) [21, 24, 25]. RARs
function as a RAR/RXR heterodimer that is activated by
RAR agonists. RXR agonists synergize with RAR ligands
to activate the heterodimer. In contrast, RXRs function
as either a homodimer or a heterodimer with a variety
of partners including RAR, peroxisome-proliferator ac-
tivated receptor (PPAR), thyroid hormone receptor, vi-
tamin D receptor, and orphan nuclear receptors [24].
Agonists and antagonists regulate RAR/RXR het-
erodimer transcriptional activity by regulating the asso-
ciation of the heterodimer with nuclear corepressors and
coactivators, which bind the heterodimer in a mutually
exclusive manner [26]. In the absence of RAR agonists,
RAR/RXR heterodimers are transcriptionally silenced
by binding corepressors. To initiate transcription, the first
step is release of corepressors from the heterodimer,
which can only be achieved by RAR, but not RXR lig-
ands; the second step is recruitment of coactivators, which
is triggered by both RAR and RXR agonists [26]. Upon
binding to a RAR agonist, RAR/RXR heterodimers re-
lease corepressors, recruit coactivators that confer his-
tone acetyltransferase activity, and initiate transcription
of a target gene. RAR and RXR agonists may synergize
in activating RAR/RXR heterodimers by collaborating
in coactivator recruitment, resulting in increased binding
and interaction efficiency of a single coactivator with the
heterodimer [26].
The specificity of retinoids in regulating gene expres-
sion is at least partially due to specific RAREs in the
target genes [24, 25]. There are three different categories
of RAREs. The most potent RARE comprises the di-
rect repeat of a consensus sequence, AGGTCA, which
is separated by several nucleotides. Less potent RAREs
are palindromic repeats, which require over-expression of
RARs for activation. Finally, the least responsive RAREs
are composed of sequences that are highly degenerate
from the consensus, and are scattered randomly along the
promoter region. Although most of the effects of tRA
and 13cRA are mediated by RAR/RXR heterodimers,
endogenously produced RXR activating metabolites
can potentially activate other RXR heterodimers or
homodimers [24].
By 2002, at least 532 tRA-regulated genes had been
described. Of these genes, only 27 have been shown to be
directly dependent on RAR/RXR and RAREs, although
another 105 appear to be candidates. Data on another
267 genes are ambivalent with regard to direct or indi-
rect regulation by RAR/RXR and RAREs. Most of the
remaining 133 genes seem to be regulated indirectly, usu-
ally through a transcriptional intermediate [25]. In gen-
eral, target genes harboring functional RAREs in their
regulatory region are immediate-early retinoid response
genes that do not require de novo protein synthesis for
activation. Retinoid-response genes with no RAREs gen-
erally require de novo protein synthesis and thus, show
somewhat slower kinetics of expression.
RAR and RXR crosstalk with other transcription factors
Retinoid-activated RAR/RXR heterodimers can pos-
itively or negatively interfere with the gene activation
mediated by other signalling pathways, including tran-
scription factors AP-1 and nuclear factor jB (NFjB). A
number of mechanisms have been implicated in the tRA-
induced anti-AP-1 activity of RAR/RXR, including:
(1) suppression of c-Fos and c-Jun expression [27–29];
(2) suppression of the c-Jun N-terminal kinase (JNK)
activity in a mitogen activated protein (MAP) kinase
phosphatase 1 (MKP-1)–dependent or –independent
manner [20, 27–29]; (3) disruption of c-Jun/c-Fos dimer-
ization [24]; (4) specific suppression of JunB-containing
dimers [30]; (5) induction of Fra-1, which lacks transcrip-
tional activity [31]; (6) suppression of JunD phospho-
rylation and RNA polymerase II recruitment, and
exclusion of CREB-binding protein (CBP) and
extracellular-regulated kinases (ERKs) from the
AP-1 binding site of the target gene promoter [31]; (7)
competition with AP-1 for coactivators [24]; and (8)
induction of the expression of RARb , which has ligand-
independent anti-AP-1 activity [32]. In resident renal
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Table 2. Categorization of retinoids
Group Description Examples References
1. Natural retinoic acid precursors (cannot bind RAR and RXR) b-carotene, vitamin A (retinol) [12, 13]
2. Natural activated retinoids, which bind RAR only all-trans-retinoic acid (tRA) [1, 6]
13-cis-retinoic acid [1, 3]
Natural activated retinoids, which bind RAR and RXR 9-cis-retinoic acid [19]
3. Synthetic retinoids
Agonists
Pan-RAR TTNPB, arotinoid [2, 4, 20]
RARa Am580, AGN195183 [3, 20]
b CD2314 [20]
c CD0666, MM11254 [20]
Pan-RXR AGN194204, Ro-257386 [2, 4, 20]
Antagonists
Pan-RAR AGN193109, ER27191 [20]
RARa AGN194301, ER50891, CD2503 [20]
b LE135, LE550 [20]
c MM11253 [20]
Pan-RXR HX531 [20]
Anti-AP-1 retinoids BMS-453 [2]
Vitamin A (Retinol)
ADHs
Retinaldehyde
Retinoic acids (RAs)
RAs bind RAR and/or RXR
RALDHs
RAR- and RXR-independent functions
Anti-AP-1, etc
RA-bound RAR/RXR or RXR/RXR binds RARE or RXRE
RA-inducible gene expression
Cyp26A/B
RA inactivation
1. RAs are essential
in renal development
2. RAs are effective
to treat kidney
diseases
Fig. 1. Biological and pharmacologic func-
tions of natural retinoids. The majority of
the functions of vitamin A (retinol) are RA-
dependent. Vitamin A does not bind RAR
and RXR, but RAs do. The conversion of vi-
tamin A to RAs is catalyzed by ADHs and
RALDHs via a reversible oxidation and an
irreversible oxidation, respectively. The ma-
jority of the functions of RAs are nuclear
receptor–dependent by initiation of target
gene expression or cross-talk with other tran-
scription factors, such as AP-1. RAs also tar-
gets nuclear receptors, kinases, and other pro-
tein substrates and, therefore, have RAR- and
RXR-independent functions. These mecha-
nisms explain why RAs play important roles
in multiple biological and pharmacologic pro-
cesses, especially during renal development
and in kidney diseases. The metabolism and
inactivation of RAs is catalyzed by a group of
cytochrome P450 (Cyp) enzymes. For exam-
ple, metabolism of tRA is mainly mediated by
Cyp26A and B.
cells, the anti-AP-1 activity of retinoids was recognized
as early as 1994 [27], and we recently reported that the
anti-AP-1 activity of retinoids is involved in both the
prevention of oxidative stress-induced apoptosis [28, 33]
and the suppression of proinflammatory molecule mono-
cyte chemoattractant protein-1 (MCP-1) expression in
glomerular mesangial cells [34].
The effects of retinoids on NFjB have been shown
to be stimulus- or cell type–specific, and both suppres-
sive [35, 36] and stimulatory [37] effects of retinoids on
NFjB have been reported. Retinoid nuclear receptors
and NFjB were reported to have mutual inhibitory activ-
ity in lipopolysaccharide (LPS)-activated macrophages
and CV-1 cells via retinoid-dependent RXR-IjBb inter-
action [36], inhibition of the NFjB-DNA interactions,
and competitive recruitment of transcription integrators
[35]. tRA was also reported to significantly reduce nu-
clear accumulation of NFjB subunits p50 and p65 in
mouse mesangial cells, which may account for the inhibi-
tion of NFjB-dependent inducible nitric oxide synthase
(iNOS) expression by tRA and 13cRA [38]. On the other
hand, tumor necrosis factor-a (TNF-a) and 9cRA have
been reported to synergistically induce intercellular ad-
hesion molecule-1 (ICAM-1) expression in endothelial
cells, via retinoid receptors and NFjB acting in concert at
the promoter level in a RARE-dependent manner [37].
Finally, RAR/RXR also interacts with other transcrip-
tion factors, such as signal transducer and activator of
transcription 5 (STAT5), CCAAT/enhancer-binding pro-
tein (C/EBP), octamer transcription factor 2A (Oct-2A),
and Sp1 [24], although these interactions are less well
characterized.
RAR- and RXR-independent roles of retinoids
Although retinoid nuclear receptor knockout results
in similar phenotypes to those seen in retinoid-deficient
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animals [39], there is emerging evidence to support a role
of nuclear receptor–independent mechanisms in the ac-
tions of retinoids in a series of biological processes. For
example, the biological effects of tRA in tRA-induced
cell growth arrest in leukemia cells have been linked
to a RAR-independent, mannose 6-phosphate/insulin-
like growth factor-II receptor (M6P/IGF2R)-dependent
mechanism [40]. In addition, tRA has been identified as a
ligand for both RAR-related orphan receptor b (RORb)
and PPARb/d. It has been shown that tRA binds RORb
with relatively low affinity (kD = 280 nmol/L) and sup-
presses its transcriptional activity in a cell type–specific
manner [41]. tRA also suppresses the transcriptional ac-
tivity of RORc, but not RORa, suggesting that it is a
selective ligand for RORb and c [41]. PPARb/d is an or-
phan nuclear receptor that has antiapoptotic effects and
mediates cell differentiation [42]. It has been reported
that tRA binds PPARb/d with nanomolar affinity, mod-
ulating the conformation of the receptor, promoting its
interaction with the coactivator SRC-1, and efficiently
activating PPARb/d-mediated transcription [42].
Some synthetic retinoids have also been found to have
nuclear receptor–independent actions. For example, syn-
thetic retinoids MX781, MX3350-1, and CD2325 induce
apoptosis of tumor cells by binding IjB kinase directly,
thereby inhibiting the NFjB activation required for cell
survival [43]. Notably, although these nuclear receptor–
independent, anti-NFjB retinoids can be antagonists or
agonists of retinoid receptors, the same mechanism was
not observed with natural RAs, indicating that this phe-
nomenon is of pharmacologic, rather than physiologic,
significance [43].
Retinoids are also involved in the post-translational
modification of proteins by binding covalently to tar-
get proteins. tRA is most likely linked to proteins via
a thioester bond, a process known as retinoylation or
RA acylation, which can occur both in vitro and in vivo
[22]. To date, at least 20 retinoylated proteins have been
detected in HL60 cells exposed to tRA, and as many
as 40 retinoylated proteins have been found in tRA-
treated NIH3T3 cells [22]. Like other post-translational
modifications of proteins, retinoylation may change the
physicochemical properties of the target molecules and
induce functional changes. For example, direct binding
of retinoids to protein kinase C (PKC) significantly alters
PKC function [44].
Retinoid-induced protein kinase activation
and suppression
Retinoids have been known to affect the activities
of various protein kinases, especially a number of PKC
isoforms, and MAP kinases ERK1/2, JNK, and p38. It
has been reported that retinoids, including tRA, sup-
press PKCb expression [45] and induce PKCa and h ex-
pression and activation [45–47]. Interestingly, a recent in
vitro study showed that pharmacologic concentrations of
tRA, 9cRA, 4-OH-tRA, and tRA glucuronide directly
bind PKCa, hampering binding of phosphatidylserine to
PKCa, and preventing PKCa activation [44]. Therefore,
the effects of retinoids on PKCa may be dose-dependent,
stimulating enzyme activity at physiologic concen-
trations, and suppressing activity at pharmacologic
concentrations. In contrast to PKCa and h, PKCd pro-
tein expression is not induced by tRA; however, tRA
significantly induces the phosphorylation and activation
of PKCd in leukemia and cancer cells [48].
We and others have reported that tRA enhances
ERK1/2 phosphorylation [20, 49]. tRA-induced ERK2
activation in HL-60 leukemia cells was reported to be de-
pendent on both RAR and RXR [49]; however, retinoids
may also induce ERK activation in a nuclear receptor–
independent manner. For example, hydroxylated retinol
metabolites directly bind PKCa with nanomolar affinity,
and markedly enhance the activation of PKCa and the en-
tire downstream ERK1/2 pathway in a redox-dependent
manner [46]. We recently reported that tRA slightly
suppressed both basal and oxidative stress–induced p38
phosphorylation in mesangial cells [20], although tRA
has also been reported to induce p38 phosphorylation in
leukemia cells [50]. tRA suppression of p38 phosphory-
lation in mesangial cells is likely due to the cell type–
specific and RAR-dependent induction of MKP-1 [20].
tRA-induced p38 phosphorylation in NB-4 leukemia cells
is also likely to be dependent on RAR since p38 phos-
phorylation was not induced in a RAR-deficient NB-4
variant [50]. In addition, tRA has both RAR-dependent
and -independent suppressive effects on JNK activity
in a number of cell types, including rat mesangial cells
[20, 29]. Conversely, in P19 embryonal carcinoma cells,
tRA induces PKC-dependent JNK activation, which is
required for tRA-induced neural differentiation [47]. Fi-
nally, retinoids also affect some other kinases, such as
protein kinase A and phosphatidylinositide 3-kinase/Akt
[51]. The biological importance of retinoid-induced pro-
tein kinase activation and suppression has recently been
reviewed by Bastien and Rochette-Egly, and notably,
most of the aforementioned protein kinases modify the
functions of retinoids in a reciprocal fashion by specifi-
cally phosphorylating retinoid nuclear receptors [51].
RETINOIDS IN RENAL DEVELOPMENT:
PHYSIOLOGIC AND PHARMACOLOGIC
IMPLICATIONS
Severe vitamin A deficiency–induced renal aplasia/
hypoplasia, horseshoe kidney, and ureteral abnormali-
ties were first reported half a century ago. More recently,
it has become clear that even moderate vitamin A defi-
ciency, which does not cause any significant abnormalities
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in other organs, results in reduced nephron number [52].
Furthermore, combined knockout of any two RAR iso-
types produces similar abnormalities to those observed in
severe vitamin A deficiency [39]. It has been established
that the malformation of both the kidney and the distal
ureter observed in vitamin A deficiency and RAR double
knockout models is due to loss of RA-induced expression
of Ret in the developing ureteric bud, which mediates the
epithelial/mesenchymal interactions and epithelial cell
remodelling needed for nephron genesis and ureter mat-
uration [53, 54]. However, the Ret gene is not a direct
target for RA and its receptors [25]. Rather, its expres-
sion in the ureteric bud is controlled by an unidentified
gene(s) in the stroma under the direct control of RA [53].
Therefore, it can be anticipated that investigation into
the direct target genes affected by RA signalling will fur-
ther advance our understanding of the role of retinoids in
renal development. Midkine, sonic hedgehog, Hox d-11,
matrix metalloproteinases, and tissue inhibitors of metal-
loproteinases have all been proposed as potential targets
of interest [55], but their exact roles are still to be defined.
For example, the midkine promoter contains a functional
RARE [56], and midkine expression is reduced in vita-
min A deficiency [57]. In in vitro studies, nephrogenesis
was strongly inhibited in the presence of neutralizing an-
tibodies for midkine; the number of nephrons formed in
vitro was reduced by approximately 50% without changes
in ureteric bud branching morphogenesis [57]. However,
since midkine knockout mice have apparently normal
kidney development [58], the role of midkine in renal
development remains to be elucidated.
If malnutrition at a critical, sensitive period of early
life has permanent effects on organ structure, physiol-
ogy, and metabolism, and therefore, influences adult life
and health, programming of the fetus may result from
adaptations invoked when the materno-placental nutri-
ent supply fails to match the fetal nutrient demand [59].
For example, fetal vitamin A deficiency also produces
adult hypertension, probably due to water retention as
a result of reduced nephron number in individuals who
experienced fetal vitamin A deficiency [59].
The role of retinoids in renal development also has
pharmacologic implications. Given the developmental
role of retinoids in regulating stem cell differentiation
and epithelial/mesenchymal interactions, it is rational to
ask whether the effective mechanisms of retinoids in
renal development are also operative in the ameliora-
tion of renal injury in acquired lesions [60]. Indeed, ac-
cumulating evidence shows that: the repair process in
the kidney also involves stem cell differentiation, cell
transdifferentiation, and epithelial/mesenchymal interac-
tions [61]; retinoid deficiency retards renal repair in the
PAN nephrosis model [6]; and human stem cells resem-
ble human embryonal carcinoma cells [62], which have
been known to be differentiated by retinoids. We have
also noted that, in a recent report by Suzuki et al, the
medium for differentiating bone marrow stem cells into
mesangial-like cells contains tRA [63].
RETINOIDS IN THE PREVENTION AND
TREATMENT OF RENAL AND URETERAL
DISEASES
Importance of vitamin A in the defense against urinary
tract infections
The susceptibility to urinary tract infections increases
in vitamin A deficiency and decreases with supplementa-
tion of vitamin A [60]. Similarly, patients with a low serum
vitamin A level have an increased susceptibility to chronic
pyelonephritis-induced renal scarring, and the severity
of renal scarring decreases with vitamin A supplemen-
tation in experimentally induced pyelonephritis in rats
[60]. In the 5/6 nephrectomy model, characterized by fo-
cal segmental glomerulosclerosis, tubular degeneration,
and interstitial fibrosis, low-dose vitamin A supplemen-
tation tends to reduce glomerular and interstitial injury,
although high-dose vitamin A exacerbates injury in both
compartments [60]. One explanation for the nephrotox-
icity of vitamin A observed in 5/6 nephrectomized rats
might be the excessive accumulation of vitamin A due to
reduced kidney mass, since the kidney is one of the most
important organs involved in vitamin A metabolism [64],
and all the major limiting enzymes of vitamin A activa-
tion and detoxification (RALDH1-3) are expressed in the
kidney [6].
Treatment of experimental mesangioproliferative
nephritis and identification of mesangial cells as
a target for RA
Wagner et al first investigated the effect of tRA
and 13cRA on acute and chronic anti-Thy1.1 mesan-
gioproliferative nephritis rat models [1, 3]. In the acute
model, it was reported that RAs completely prevented
hypertension and renal failure, dramatically reduced
proteinuria, significantly reduced intraglomerular cell
proliferation, capillary occlusion, macrophage infiltra-
tion, and fibrin deposition, while the expression of
platelet-derived growth factor B-chain (PDGF-B), trans-
forming growth factor (TGF) b1, and its receptor was
inhibited [1, 65]. In the chronic model, 13cRA not
only reduced blood pressure and albuminuria, but also
prevented glomerulosclerosis, interstitial fibrosis, and
macrophage infiltration [3]. The dramatic antihyperten-
sive effect of RAs in nephritic rats might be due to
the suppressive effect of RAs on the renin-angiotensin
system (RAS). For example, tRA significantly reduced
both serum angiotensin-converting enzyme (ACE) ac-
tivity and mRNA levels of all the RAS components
examined in the renal cortex [66]. Since tRA inhibits
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angiotensin II–stimulated c-fos expression, down-
regulates the AT1 receptor, and antagonizes the functions
of angiotensin II in vitro [66–68], it is likely that tRA also
directly antagonizes angiotensin II. Indeed, 13cRA ef-
fectively prevented hypertension and intrarenal TGFb
expression induced by chronic angiotensin II infusion
[abstract; Schade K et al, J Am Soc Nephrol 12:473A,
2001].
Wagner’s group also used synthetic retinoid receptor–
specific agonists to treat established chronic anti-Thy1.1
nephritic rats. They compared an RARa-selective ag-
onist (AGN195183) and an RXR-selective agonist
(AGN194204) and found that both had comparable
effects on blood pressure, proteinuria, glomerulosclero-
sis index, glomerular macrophage infiltration, glomeru-
lar TGF-b1, and prepro-endothelin-1 (prepro-ET-1)
expression and interstitial expansion [4]. In another se-
ries of experiments, a RAR agonist, arotinoid, a RXR
agonist, Ro-257386, and an anti-AP-1 retinoid, BMS-
453, were used to treat anti-Thy1.1 nephritis. These three
compounds similarly suppressed glomerular cell prolifer-
ation and macrophage infiltration and inhibited glomeru-
lar ET-1 and ET-1 receptor expression, but differed in
preventing hypertension, albuminuria, and renal failure.
In summary, BMS-453 was most effective in reducing al-
buminuria and was moderately effective in preventing
hypertension and renal failure; Ro-257386 most potently
reduced blood pressure, moderately reduced proteinuria,
but was not effective in restoring renal function; arotinoid
was most effective in preventing renal failure, although it
did not significantly prevent either hypertension or pro-
teinuria [2].
Anti-Thy1.1 glomerulonephritis is induced by anti-
Thy1.1 antibody, which specifically targets mesangial cells
[1, 3]. One of the important contributions of the afore-
mentioned animal studies is in providing in vivo evidence
to support the idea that mesangial cells are a target for
the therapeutic actions of retinoids [19], which has been
suggested by the following in vitro findings: (1) both rat
and human mesangial cells express all RAR and RXR
isotypes [19, 20]; (2) RAs inhibit proliferation [19, 27],
regulate apoptosis [19, 20, 28, 29, 33]; and suppress os-
teopontin, fibronectin [19], MCP-1 [34], and iNOS [38]
expression in mesangial cells.
Treatment of puromycin aminonucleoside (PAN)
nephrosis: Identification of podocytes as a target for
RA and elucidation of the RA signal as a built-in
feedback protection mechanism
PAN nephrosis, which resembles human minimal
change nephrosis, is characterized by nephrotic syndrome
and damage to podocytes [5]. Our recent work showed
that tRA administered orally starting either on the day
of PAN injection or two days after PAN injection al-
most completely prevented PAN-induced proteinuria.
Delayed administration of tRA starting four days after
PAN injection had no effect on the peak of proteinuria at
day nine, but still reduced proteinuria to less than half of
the untreated controls at day 16 [5]. These data indicate
that tRA might have both prophylactic and therapeutic
effects on PAN-induced kidney injury, possibly due to
the ability of tRA to prevent PAN-induced apoptosis of
podocytes and to suppress interstitial mononuclear cell
infiltration and inhibit MCP-1 and fibronectin expression
[5]. The efficacy of tRA in preventing PAN nephrosis is
also supported by a recent report by Suzuki et al, show-
ing that a vitamin A–deficient diet increased, while ex-
ogenous tRA suppressed, PAN-induced proteinuria, and
tRA might promote the repair of the glomerular filtration
barrier by specifically inducing the expression of nephrin
in podocytes [6]. These investigators also reported that
both RALDH2 and RARa were selectively and strongly
expressed in podocytes, but not in endothelial and mesan-
gial cells in PAN-nephrotic rats, indicating that podocytes
are not only a major natural source of, but also a major
target for, RAs in vivo [6]. This is further supported by
our in vitro data that tRA prevents PAN-induced apop-
tosis in a podocyte cell line [5].
Treatment of experimental systemic lupus erythematosus
(SLE) and influence of retinoids on immunity
We recently examined the effect of tRA on MRL/lpr
mice, an animal model of human SLE, and found that
tRA significantly reduced proteinuria, inhibited lym-
phoadenopathy and splenomegaly, prevented glomeru-
lar hypercellularity, mesangial expansion, and intersti-
tial inflammatory infiltration, and inhibited RANTES
(regulated on activation, normal T cells expressed and
secreted), macrophage inflammatory protein-1 (MIP-
1), and MCP-1 expression, although it affected neither
plasma immunoglobulins (Igs), anti-DNA antibody, nor
glomerular deposition of IgG and C3 [abstract; de Lema
GP et al, J Am Soc Nephrol 13:F174A, 2002].
Kinoshita et al recently used NZB/NZW F1 mice,
another murine SLE model, to examine the effects of
tRA on experimental SLE [7]. Notably, in this model,
at eight months of age, there was no significant change
in renal histology, proteinuria, and mortality in the
tRA-treated group, whereas most of the vehicle-treated
animals developed significant glomerular, tubular, and
interstitial changes, more than 50% developed signif-
icant proteinuria, and there was 40% mortality. tRA
also significantly reduced the number of infiltrating T
cells, B cells, and macrophages in the periglomerular,
interstitial, and perivascular areas. tRA-treated mice
had significantly less glomerular deposition of total
IgG, IgG2a, and IgG2b, and significantly reduced serum
levels of anti-DNA antibodies, especially the IgG2a
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isotype. Splenomegaly was less marked, and the levels
of interferon-c (IFN-c), interleukin-2 (IL-2), and IL-10
expression in splenic CD4+ T cells, as well as the serum
levels of these factors, were dramatically reduced in
tRA-treated mice [7].
The seemingly conflicting findings in MRL/lpr mice and
those in NZB/NZW F1 mice lie in the influence of tRA
on immune complex deposition. Our studies showed that
tRA suppressed renal injury without affecting glomeru-
lar deposition of IgG and C3 [abstract; de Lema GP
et al, J Am Soc Nephrol 13:F174A, 2002]. In contrast,
Kinoshita et al found that tRA significantly suppressed
IgG deposition [7]. This can be explained by the isotype
difference of the anti-DNA antibody IgG in these two
models. In MRL/lpr mice, the major pathogenic circu-
lating anti-DNA antibody, which is also deposited in the
glomeruli, is of the IgG3 isotype [69]; however, in NZB/W
F1 mice, the complement-fixing IgG2a anti-DNA anti-
body is predominantly nephritogenic [7]. In fact, tRA
did not suppress plasma IgG3 and glomerular deposi-
tion of IgG3 even in NZB/NZW F1 mice, although the
IgG2a anti-DNA antibody was significantly suppressed
by tRA [7]. Therefore, it seems that tRA may protect the
kidneys both upstream (as in NZB/NZW F1 mice) and
downstream (as in MRL/lpr mice) of immune complex
deposition.
Retinoids modulate the immune response by regulat-
ing a shift between the responses of Th1 and Th2 lympho-
cytes. In vivo findings that vitamin A deficiency changed
the immune response from a Th2-type to a Th1-type re-
sponse [70], and the in vitro observations that tRA and
vitamin A inhibit Th1 cytokine production by T cells
[71], are further supported by the findings of Kinoshita
et al that tRA dramatically suppressed Th1 cytokines
IFN-c and IL-2, but not the Th2 cytokine IL-4 and im-
munoglobin isotypes IgG1 and IgG3 [7].
Intriguingly, retinoids are not only potent inhibitors
of autoimmune injury, but also important mediators of
normal immune activities against infection and play a
role in the development of both T-helper cells and B
cells [72]. Vitamin A treatment of SLE patients and
healthy controls resulted in an enhancement of antibody-
dependent cell-mediated cytotoxicity, natural killer ac-
tivity, and blastogenic response to mitogens [73]. In acne
patients, a synthetic retinoid, etretinate, also increased
natural killer cell number and activity, whereas 13cRA
significantly reduced natural killer cell number and ac-
tivity [74]. One mechanism of the immunomodulation
by retinoids is probably by influencing spontaneous and
activation-induced apoptosis of T lymphocytes in a RAR-
and RXR-dependent manner [75]. Interestingly, different
RAR isotypes may have different roles in regulating the
immune system, because selective activation of RARc
induces apoptosis of T cells, while specific stimulation of
RARa prevents RARc-dependent T-cell apoptosis [75].
Another recently identified mechanism of the immune-
enhancing effects of retinoids is the RAR-dependent in-
duction of T-cell proliferation and IL-2 secretion [76].
Amelioration of renal damage in experimental acute
renal allograft rejection
It was reported some time ago that a synthetic retinoid,
Ro23-6457, significantly prolonged the survival of rat
cardiac allografts [77]. Recently, the effect of 13cRA
on acute renal allograft rejection was examined in a
rat model. 13cRA significantly reduced albuminuria and
serum creatinine, and significantly prevented acute vas-
cular injury, acute glomerular injury, glomerular mono-
cyte, macrophage and cytotoxic T-cell infiltration, as
well as suppressing tubulointerstitial cell proliferation
and inflammatory cell infiltration [8]. These data fur-
ther suggest a role for retinoids in transplantation
immunosuppression.
Treatment of experimental anti-glomerular basement
membrane (anti-GBM) glomerulonephritis
Rat anti-GBM glomerulonephritis is an analog of hu-
man type I crescentic glomerulonephritis. Datta et al re-
ported that tRA, administered orally for two weeks at
5 mg/kg/day starting immediately before immunization
with anti-GBM antibody, did not affect proteinuria in the
anti-GBM glomerulonephritis model at day 14, although
it markedly reduced intraglomerular cell proliferation,
significantly suppressed the activity of the proinflamma-
tory molecule, iNOS, and enhanced the expression of the
anti-inflammatory molecule, TGF-b1, in glomeruli [15].
Recently, Oseto et al used a different strategy to treat
anti-GBM glomerulonephritis rats. In rats given tRA,
30 mg/kg/day, starting two weeks after immunization with
anti-GBM antibody, they found that: (1) tRA significantly
reduced proteinuria and blood pressure; (2) tRA signifi-
cantly reduced glomerular damage suppressing crescent
formation and macrophage infiltration; and (3) tRA sig-
nificantly reduced the expression of mRNAs for TNFa,
IL-1b , PDGF, MCP-1, ICAM-1, TGFb1, collagen I, as
well as a-smooth muscle actin [14].
Both studies support the idea that tRA has anti-
inflammatory effects in the anti-GBM nephritis model.
The different effects of tRA on proteinuria in these two
studies might be explained by the different tRA concen-
trations, the different experimental design, or differences
in the timing of treatment. It is interesting that tRA in-
creased TGF-b1 expression in the acute inflammatory
phase of the disease model [15], but reduced TGF-b1 ex-
pression in the later stage of the disease [14]. Based on
the dual functions of TGF-b on inflammation and fibrosis,
it is possible that tRA conditionally influences TGF-b1
expression, namely increasing TGF-b1 in the acute in-
flammatory phase of nephritis to suppress inflammation,
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and decreasing TGF-b1 in the later stage of the nephri-
tis to prevent glomerulosclerosis and interstitial fibrosis.
The conditional induction and suppression of TGF-b1
expression by tRA has also been reported in cultured
kidney fibroblasts [78].
Treatment of glomerulosclerosis and interstitial fibrosis:
Retinoids have direct antisclerotic and antifibrotic
actions, and may directly target tubulointerstitial cells
In experimental models of glomerular diseases such
as anti-Thy1.1 nephritis [3, 65] and PAN nephrosis
[5], retinoids have been reported to reduce extracel-
lular matrix (ECM) accumulation in glomeruli and
the renal interstitium. However, since retinoids have
strong anti-inflammatory effects on glomerular mesan-
gial cells, podocytes and immune/inflammatory cells, two
further questions need to be addressed: are the antifi-
brotic and antisclerotic effects independent of the anti-
inflammatory effects, and are the antifibrotic effects on
the interstitium independent of the beneficial effects on
glomeruli?
Our studies on progressive glomerular sclerosis in ag-
ing rats, a non-nephritic model of renal fibrosis, suggest
that tRA might well prevent glomerulosclerosis in a man-
ner independent of inflammation [9, 10]. In these studies,
18-month-old male Fischer 344 rats were fed with stan-
dard chow with or without a low dose of tRA (1 mg/kg/day
vs. 10 mg/kg/day for treatment of PAN nephrosis) for
three months. tRA significantly increased the glomerular
filtration rate [9] and suppressed TGF-b expression [10]
in the renal cortex. Since glomerular hydrogen peroxide
(H2O2) production increases in glomerulosclerosis and,
in vitro, H2O2 induces apoptosis of mesangial cells [33],
we hypothesize that tRA prevents loss of resident renal
cells by inhibiting H2O2-induced apoptosis. Indeed, we
found that tRA potently inhibits H2O2-induced apopto-
sis in both rat and human mesangial cells by induction of
MKP-1 and inhibition of the JNK-AP-1 pathway [9, 10,
19, 20, 28, 29, 33].
tRA not only targets glomerular mesangial cells and
podocytes, but also directly targets renal fibroblasts. As
shown in Figure 2, our recent unpublished data indi-
cated that tRA significantly prevented TGF-b1–induced
fibronectin mRNA expression in human renal fibroblasts.
These in vitro data, together with the demonstrated ef-
ficacy of tRA in treating unilateral ureter obstruction-
induced tubulointerstitial nephritis [11], argue in favor of
a direct protective effect of tRA on the tubulointersti-
tial injury, independent of any protective effects on the
glomeruli, and lend support to our hypothesis that tRA
has inflammation-independent antifibrotic actions. Other
reported effects of retinoids on renal tubular and inter-
stitial cells include: (1) tRA significantly stimulates renal
tubular epithelial cell proliferation with [79] or without
Fibronectin
GAPDH
TGF-β
tRA
− + − +
− − + +
Fig. 2. Effects of tRA on TGFb-induced fibronectin mRNA expres-
sion in human renal fibroblasts. Confluent human renal fibroblasts were
made quiescent in DMEM:Ham’s F12 (1:1) medium containing 0.1%
fetal calf serum (FCS) for 48 hours before being treated with 5 ng/mL
TGFb1 for 24 hours and 48 hours in the absence or presence of 1 lmol/L
tRA. Total RNA was extracted and subjected to Northern hybridiza-
tion for fibronectin and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNAs. A representative Northern blot of cells treated
for 24 hours is shown (48-hour experiments show a similar trend; data
not shown).
[80] significant hypertrophy, and therefore might be in-
volved in the functional compensation, hypertrophy, and
repair of renal tubules; (2) in normal rat kidney fibrob-
lasts tRA promotes secretion of TGF-b2 and decreases
TGF-b1 expression [78].
POTENTIAL ADVANTAGES OF RETINOIDS IN
TREATMENT OF RENAL DISEASES
Based on the accumulating data, it is to be antici-
pated that retinoids might prove useful in the treatment
of various renal conditions, some of which, such as hy-
pertensive nephropathy, focal-segmental glomeruloscle-
rosis, pyelonephritis, and renal interstitial fibrosis, are
contraindicated in the use of glucocorticoids.
One of the most important adverse effects of gluco-
corticoids and cytotoxic agents is the risk of infection. In
contrast, as shown in Table 1, retinoids have been used in
both infective and noninfective renal inflammation, and
have rarely been reported to induce severe acquired in-
fection in patients. This might be due to the fact that the
effect of retinoids on immunity is “immune modulation”
rather than a nonspecific “immune suppression,” as de-
scribed in the above section.
High blood pressure and intrarenal activation of the
renin-angiotensin and the endothelin systems are com-
mon findings in severe renal diseases. Retinoids can in-
tervene in both these systems to reduce blood pressure.
Furthermore, retinoids have protective effects on blood
vessels and the heart in a blood pressure–independent
manner [81, 82]. These effects contrast with those of glu-
cocorticoids, which enhance blood pressure by inducing
water retention and increasing plasma angiotensinogen
concentration secondary to increased hepatic synthesis.
A procoagulative state is another important factor
in glomerulonephritis. The conventional medication,
glucocorticoids, induces hypercoagulation and hypofib-
rinolytic activity. In contrast, tRA has been shown to
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induce the anticoagulation molecule, thrombomodulin,
and the profibrinolytic enzyme, urokinase [83, 84], and to
be effective in the treatment of endotoxin-induced dis-
seminated intravascular coagulation (DIC) in rats [85].
Agonists of RAR and RXR, as well as selective anti-
AP-1 retinoids, have been demonstrated to be effective
in treating nephritic animals, although they might be dif-
ferentially effective in preventing hypertension, protein-
uria, and renal failure [2]. Since there are three isotypes
of both RAR and RXR with overlapping and distinct
functions, it is rational to ask whether it is possible to use
retinoid nuclear receptor isotype-selective ligands for a
given indication to minimize side effects. Indeed, tRA-
induced skin irritation and cytotoxicity are largely due to
the activation of RARc, but not RARa, and therefore, a
selective RARa agonist has been successfully used to re-
duce side effects [86, 87]. In keratinocytes, in which there
is no expression of RARb , gene knockout of RARa and c
induces distinctive changes in the pattern of gene expres-
sion, further suggesting that RAR a and c have unique
functions [88]. In mesangial cells, which express all RAR
isotypes, RARb has a distinctive role in regulating MKP-
1 expression when compared with RAR a and c [20].
These data suggest that isotype-selective RAR agonists
may have different therapeutic efficacy with varying side
effects.
Another advantage of retinoids in the treatment of re-
nal diseases in man compared with other new medications
is that retinoids have been used to treat other diseases
for many years; hence, information on the side effects of
retinoids such as tRA and 13cRA is readily available. In
the treatment of leukemia, combined use of retinoids and
glucocorticoids has been shown to have synergistic effects
in inducing differentiation and inhibiting proliferation of
leukemia cells and to reduce major adverse effects [89].
It is possible that, in view of their distinctive mechanisms
of actions and given the synergistic inhibition of mesan-
gial cell proliferation in vitro [abstract; Kaname S et al,
J Am Soc Nephrol 13:297A, 2002], retinoids and glucocor-
ticoids also synergize in the treatment of renal diseases.
POTENTIAL LIMITATIONS OF RETINOIDS IN
TREATMENT OF RENAL DISEASES
Reported side effects of retinoids
Although most studies in rodents have found few
side effects of retinoids, a number of major side ef-
fects in patients besides some minor ones, such as el-
evated serum lipids, generalized xerosis, and alopecia,
have been documented in the literature. For instance,
the well-known teratogenic effect of retinoids may lead
to severe birth defects, and it has been proposed that
contraception should be used during retinoid therapy
and for two years afterwards [90]. Another important
side effect is the risk of retinoids to the central ner-
vous system. For example, in animal studies, 13cRA has
been shown to suppress hippocampal cell division and
hippocampal-dependent learning [91], and reports of in-
tracranial hypertension, depression, and suicidal ideation
with retinoid use have prompted an examination of their
serious and life-threatening potential [90]. Finally, induc-
tion therapy of acute promyelocytic leukemia with tRA
is standard, despite significant side effects, of which the
most important is “RA syndrome,” in which there is a
hyperinflammatory reaction with capillary leakage, infil-
tration of myeloid cells into internal organs, and systemic
signs of inflammation. Where “RA syndrome” occurs,
administration of tRA must be terminated and replaced
by corticosteroids. Fortunately, since “RA syndrome” is
a syndrome of tissue infiltration by maturing myeloid
cells, which only occurs during induction treatment of
leukemia with tRA or other medications, the syndrome
is specific to leukemia patients, even in the absence of
tRA treatment [92], and it is unlikely that it will be a
significant side effect of tRA use in nephritis patients.
Evidence of the proinflammatory effects of retinoids
Although the severe inflammatory “RA syndrome” is
unlikely to happen in renal patients treated with retinoids,
the possibility that retinoids might have proinflamma-
tory effects in patients with renal diseases cannot be
excluded. Emerging evidence indicates that, although
retinoids are potent anti-inflammatory agents, they may
also have proinflammatory potential by inducing some
proinflammatory molecules. For example, retinoids can
induce iNOS expression in vivo [93], and enhance
IL-8 [94] and ICAM-1 [37] expression in vitro. Further,
since tRA has been shown to potentiate tubulointerstitial
nephritis both in patients and in animal models [16, 17],
retinoids may also have proinflammatory effects on re-
nal tubulointerstitial cells. In support of this hypothesis,
midkine, a RA-inducible gene product, is reported to be
involved in neutrophil infiltration in the tubulointersti-
tium in ischemic renal injury [95].
We also found that retinoids only have suppressive
effects on selected inflammatory mediators induced by
selected stimuli. For example, although tRA suppresses
the constitutive expression of MCP-1 in rat mesangial
cells, it does not affect IL-1b–induced MCP-1 expres-
sion [34]. Further, tRA and 9cRA did not suppress,
but rather enhanced, the expression of MIF, COX-1,
COX-2, and VCAM-1 in human and rat mesangial cells
[abstract; Xu Q et al, J Am Soc Nephrol 14:86A, 2003].
The biological significance of RA-induced expression of
these proinflammatory molecules is not clear; we specu-
late that the RA-inducible pro-inflammatory molecules
might be related to the resistance to and proinflamma-
tory side effects of tRA (Fig. 3). Interestingly, although
tRA has some advantages compared to glucocorticoids
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Group A
Inflammatory
factors
Group B
Inflammatory
factors
Group C
Inflammatory
factors
Disease A Disease C
Disease D Disease E
Disease F
Disease B
Fig. 3. Different effects of retinoids on varying groups of proinflam-
matory factors might contribute to the different responses of renal dis-
eases to retinoid treatment. Inflammatory factors are theoretically di-
vided into three groups, which respond differentially to RA treatment,
namely, RAs suppress group A, induce group C, and have little influ-
ence on group B. Consequently, the group A and group D diseases that
are mediated by group A or group A plus group B inflammatory fac-
tors are good indicators for RA treatment; the group B diseases that
are solely mediated by group B inflammatory factors are not responsive
to RAs; the group C and group E diseases that are mediated by group
C inflammatory factors only or by group C plus group B factors are
not indicators for retinoid treatment, and may even be exacerbated by
retinoids. The group F diseases that are mediated by both group A and
group C inflammatory factors may become resistant to RAs, or may
respond to retinoids, but at the same time develop some inflammatory
side effects. The solid line with a circled ‘minus’ indicates a suppression;
the solid line with a circled ‘plus’ stands for induction. The dashed line
indicates no interaction.
(as described in the previous section), our recent unpub-
lished data showed that tRA-induced MIF expression in
cultured human mesangial cells can be inhibited by dex-
amethasone (Fig. 4), suggesting that, just as in the case
of “RA syndrome,” glucocorticoids might be useful to
antagonize the proinflammatory side effects of tRA.
Do retinoids have atherogenic potential?
Despite the recent reports that tRA reduced the early
neointimal proliferation and artery restenosis in a bal-
loon angioplasty model of rabbit [96], and that RXR ag-
onists prevented hyperlipidemia-induced atherosclerosis
[97], we have found that tRA dramatically induces low-
density lipoprotein (LDL) accumulation in smooth mus-
cle cells [abstract; Xu Q et al, J Am Soc Nephrol 14:86A,
2003] (Fig. 5). In addition, tRA has also been reported to
induce oxidized LDL accumulation in macrophages by
inducing CD36 expression in a RAR-dependent manner
[98]. Since LDL accumulation in smooth muscle cells and
macrophages is central to the pathogenesis of atheroscle-
rosis, and given that human atherosclerotic plaques con-
MIF
tRA 0 0.01 0.1 1 5 10 (µmol/L)
28S rRNA
A
MIF
Dex 0 0.01 0.1 1 5 (µmol/L)
28S rRNA
B
MIF
Dex 0 5 0 5 (µmol/L)
tRA 0 0 5 5 (µmol/L)
28S rRNA
C
Fig. 4. The effects of tRA and dexamethasone (Dex) on MIF mRNA
expression in human mesangial cells. Cultured human glomerular
mesangial cells were made quiescent in RPMI 1640 medium containing
0.5% FCS for 24 hours prior to treatment with (A) 0 to 10 lmol/L tRA,
(B) 0 to 5 lmol/L Dex, or (C) 0 to 5 lmol/L tRA and/or Dex for 24
hours. Total RNA was extracted and subject to Northern hybridization
for MIF mRNA and 28S ribosomal RNA (rRNA). A representative
Northern blot analysis is shown.
A B
Fig. 5. tRA increased LDL accumulation in pig smooth muscle cells:
Oil Red O staining. Pig artery smooth muscle cells were cultured in
RPMI 1640 medium containing 1% FCS for 24 hours and followed by a
further 24 hours in RPMI 1640, 1% FCS supplemented with 200 lg/mL
LDL in the absence (A) or presence (B) of 5 lmol/L tRA. Cells were
washed three times with cold phosphate-buffered saline, fixed with 5%
formalin and subjected to Oil Red O staining. The arrow in (B) points
to an LDL droplet visualized by Oil Red O staining.
tain 10-fold increased concentrations of RA and have
activated RAR expression [98], it is important to deter-
mine whether long-term use of retinoids will increase the
mortality from cardio- and cerebrovascular diseases.
CONCLUSION AND PERSPECTIVES
Retinoids play an important role in renal development,
and nephrogenic hypertension might be programmed by
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fetal vitamin A deficiency, a common condition in preg-
nant women [59, 99]. Therefore, maintaining an ade-
quate vitamin A supply and liver reserve in pregnant
women should prevent vitamin A deficiency in the fe-
tus, and might help prevent hypertension and renal dis-
eases in adults. Paradoxically, too much vitamin A can
also severely affect normal development, although ex-
cessive dietary intake of vitamin A has been associated
with teratogenicity in fewer than 20 individuals in over
30 years [99]. Therefore, vitamin A supplementation
should be approached with caution, taking into account
the estimated vitamin A status of a pregnant woman
and whether supplementation can be appropriately su-
pervised. On the other hand, it might also be very harmful
for pregnant women to simply abstain from foods rich in
vitamin A in order to avoid the potential teratogenicity
of vitamin A. It is advisable to routinely monitor the liver
reserve, serum, and milk vitamin A levels in pregnant
women so that both hypo- and hypervitaminosis A in fe-
tus can be prevented [100].
In the adult, retinoids target mesangial cells, podocytes,
tubular epithelial cells, interstitial fibroblasts, as well
as T lymphocytes and macrophages, and have anti-
inflammatory, anticoagulatory, antifibrotic effects and
proliferation- and immunity-modulating actions. All
these features make retinoids a promising new generation
of renal medication for use in a variety of renal diseases.
The pharmacologic effects of retinoids reported in an-
imal studies suggest that it may be worthwhile to ex-
amine whether retinoids can be useful in dealing with
the following conditions: (1) steroid-resistant glomeru-
lonephritides, such as focal segmental glomerulosclerosis,
membranous nephropathy, and membranous prolifera-
tive glomerulonephritis; (2) glomerulonephritis respon-
sive to but developing secondary resistance to steroids,
such as refractory minimal change nephrosis, mesangio-
proliferative glomerulonephritis; (3) glomerulonephritis
with mild to moderate chronic renal failure and renal fi-
brosis; (4) glomerulonephritis complicated by diabetes
or other side effects of steroids; (5) crescentic glomeru-
lonephritis; (6) SLE and lupus nephritis; (7) renal trans-
plantation. We suggest that comprehensive clinical trials
of retinoid treatment of renal diseases should be car-
ried out to further examine the therapeutic potential of
retinoids.
Given the reduced incidence of “RA syndrome”
and the suppression of tRA-induced proinflammatory
molecule expression with the combined use of retinoids
and steroids, it will also be important to establish whether
combination therapy using lower doses of both com-
pounds can achieve better therapeutic outcomes than ei-
ther compound alone. In vitro studies to directly compare
the effects of steroids, retinoids, or combination of the two
on kidney cells and immune cells exposed to different
stimuli will provide further insights into the advantages
and disadvantages of these two groups of compounds and
their combined use.
Any future clinical trials will have to provide careful
monitoring of both major side effects, such as terato-
genicity and depression, and other minor side effects. Al-
though retinoids are unlikely to induce “RA syndrome”
in patients with renal disease, retinoid induction of proin-
flammatory molecules in mesangial cells suggests that
primary and secondary resistance and inflammatory side
effects may occur. In view of the potential of tRA to in-
duce LDL and modified LDL accumulation in smooth
muscle cells and macrophages, careful examination will
be required to determine whether, among other adverse
effects, retinoids have atherogenic potential. Finally, it
remains to be tested whether RAR and RXR isotype-
selective retinoids increase the benefit/risk ratio in kidney
diseases.
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